Since the down-regulation of DUSP22 expression in CD4+ T cells was also correlated with the presence and activity of Systemic Lupus Erythematodes (SLE) in human patients, DUSP22 is emerging as a biomarker for several autoimmune diseases [160]. Here, DUSP22 is linked to autoimmune disease.